[go: up one dir, main page]

WO1990003798A3 - Agents ciblants - Google Patents

Agents ciblants Download PDF

Info

Publication number
WO1990003798A3
WO1990003798A3 PCT/GB1989/001180 GB8901180W WO9003798A3 WO 1990003798 A3 WO1990003798 A3 WO 1990003798A3 GB 8901180 W GB8901180 W GB 8901180W WO 9003798 A3 WO9003798 A3 WO 9003798A3
Authority
WO
WIPO (PCT)
Prior art keywords
targetting
agents
targetting agents
msh
analogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1989/001180
Other languages
English (en)
Other versions
WO1990003798A2 (fr
Inventor
David Peter Page-Thomas
David Roy Bard
Clive Graham Knight
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Original Assignee
Cancer Research Campaign Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888823208A external-priority patent/GB8823208D0/en
Priority claimed from GB898900988A external-priority patent/GB8900988D0/en
Priority claimed from GB898914526A external-priority patent/GB8914526D0/en
Application filed by Cancer Research Campaign Technology Ltd filed Critical Cancer Research Campaign Technology Ltd
Priority to DE68913753T priority Critical patent/DE68913753T2/de
Priority to AT89911284T priority patent/ATE102485T1/de
Publication of WO1990003798A2 publication Critical patent/WO1990003798A2/fr
Publication of WO1990003798A3 publication Critical patent/WO1990003798A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

On décrit un produit de formule (I): R-(M)n, dans laquelle n est plus grand que 1, chaque M est un polypeptide à liaison N-terminale choisi parmi une hormone mélanostimulante alpha (MSH), ses dérivés et ses analogues, et R est une fraction de molécule ciblée que l'on peut éventuellement lier aux groupes M par un groupe de liaison.
PCT/GB1989/001180 1988-10-04 1989-10-04 Agents ciblants Ceased WO1990003798A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE68913753T DE68913753T2 (de) 1988-10-04 1989-10-04 Zielmittel.
AT89911284T ATE102485T1 (de) 1988-10-04 1989-10-04 Zielmittel.

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB8823208.7 1988-10-04
GB888823208A GB8823208D0 (en) 1988-10-04 1988-10-04 Targetting agents
GB8900988.0 1989-01-17
GB898900988A GB8900988D0 (en) 1989-01-17 1989-01-17 Targetting agents
GB8914526.2 1989-06-23
GB898914526A GB8914526D0 (en) 1989-06-23 1989-06-23 Targetting agents

Publications (2)

Publication Number Publication Date
WO1990003798A2 WO1990003798A2 (fr) 1990-04-19
WO1990003798A3 true WO1990003798A3 (fr) 1990-06-14

Family

ID=27264108

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1989/001180 Ceased WO1990003798A2 (fr) 1988-10-04 1989-10-04 Agents ciblants

Country Status (6)

Country Link
EP (1) EP0437487B1 (fr)
JP (1) JPH04500805A (fr)
AU (1) AU635721B2 (fr)
DE (1) DE68913753T2 (fr)
NZ (1) NZ230897A (fr)
WO (1) WO1990003798A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2070329T3 (es) * 1989-07-20 1995-06-01 Sandoz Ltd Derivados de polipeptidos.
GB9102450D0 (en) * 1991-02-05 1991-03-20 Sandoz Ltd Improvements in or relating to organic compounds
US5508020A (en) 1992-06-05 1996-04-16 Diatech, Inc. Technetium-99M labeled peptides for imaging
FR2691465B1 (fr) * 1992-05-25 1995-08-11 Pf Medicament Complexes comprenant au moins un peptide derive de l'alpha msh, peptide, microsphere, medicament et composition galenique les comprenant.
US5951964A (en) * 1993-06-04 1999-09-14 Diatide, Inc. Technetium-99m labeled peptides for imaging
US6866837B2 (en) 1998-06-05 2005-03-15 Mallinckrodt Inc. Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors
EP3328372A4 (fr) 2015-07-28 2019-03-20 University Of Iowa Research Foundation Compositions et méthodes de traitement du cancer
WO2017223565A1 (fr) 2016-06-24 2017-12-28 University Of Iowa Research Foundation Compositions et procédés de traitement d'un mélanome
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0094844A2 (fr) * 1982-05-18 1983-11-23 The Regents Of The University Of California Conjugués d'agents pharmaceutiques-véhicules
EP0268707A2 (fr) * 1985-11-05 1988-06-01 The General Hospital Corporation Réactifs d'affinité spécifique portant une charge négative

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ234173A (en) * 1989-06-23 1993-10-26 Cancer Res Campaign Tech Alpha-melanocyte stimulating hormone derivative (alphamsh)-targetted moiety conjugate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0094844A2 (fr) * 1982-05-18 1983-11-23 The Regents Of The University Of California Conjugués d'agents pharmaceutiques-véhicules
EP0268707A2 (fr) * 1985-11-05 1988-06-01 The General Hospital Corporation Réactifs d'affinité spécifique portant une charge négative

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biochemical Society Transactions, Volume 14, 1986, (London, GB), D.R. BARD et al.: "Targetting of a Radionuclide to Cloudman Melanoma Cells in Vitro and in Vivo", pages 614-615 *
Proc. Natl. Acad. Sci. USA, Volume 83, November 1986, (Washington, D.C., US), J.R. MURPHY et al.: "Genetic Construction, Expression, and Melanoma-Selective Cytotoxicity of a Diphtheria Toxin-Related alfa-Melanocyte-Stimulating Hormone Fusion Protein", pages 8258-8262 *

Also Published As

Publication number Publication date
AU635721B2 (en) 1993-04-01
DE68913753D1 (de) 1994-04-14
DE68913753T2 (de) 1994-08-11
JPH04500805A (ja) 1992-02-13
EP0437487A1 (fr) 1991-07-24
NZ230897A (en) 1993-02-25
EP0437487B1 (fr) 1994-03-09
AU4403289A (en) 1990-05-01
WO1990003798A2 (fr) 1990-04-19

Similar Documents

Publication Publication Date Title
ES8704973A1 (es) Un procedimiento para la preparacion de un peptido.
CA2168113A1 (fr) Derives de peptides, agents therapeutiques
DK193887A (da) Peptid med bronchodilartorisk og hypotensiv aktivitet
WO1990003798A3 (fr) Agents ciblants
EP0363589A3 (fr) Analogues de somatostatine
NZ231353A (en) Pharmaceutical compositions comprising 3,5-dihydroxy-7-(1-acyloxyhexahydronaphth-8-yl)-heptanoic acid and lactone derivatives
EP0225020A3 (fr) Peptides comprenant dans leur séquence des unités sélectionnées parmi les restes d'acides aminés 17 à 24 du VIP
IL74066A0 (en) 6,6-ethylene-15,16-methylene-3-oxo-17alpha-pregn-4-ene-21,17-carbolactones,processes for the production thereof,and pharmaceutical preparations containing them
ATE130312T1 (de) Polypeptid mit sich wiederholenden zelladhäsiven hauptsequenzen.
HUT58765A (en) Process for producing peptide compounds and pharmaceutical compositions containing them as active components
WO1993018055A3 (fr) Peptide stimulant la reponse des lymphocytes cytotoxiques a la gp160 du vih-1
IL59603A (en) Peptides having ubiquitin-like activity,their preparation and pharmaceutical compositions containing them
ZA879579B (en) Pharmaceutical delivery systems resolution of 1,4-dihydropyridine derivatives
WO1990006943A3 (fr) Nouveaux peptides tnf
AU2687188A (en) New derivatives of cyclic amino acids, a process for the preparation thereof, agents containing them, and the use thereof
AU587626B2 (en) Continuous release peptide composition
ZA888799B (en) Derivatives of paraherquamide isolated from a permentation broth active as antiparasitic agents
IE781291L (en) Psychopharmacological peptides
AU4792290A (en) Novel peptides inhibiting the maturation of t-lymphocytes and the activity of macrophages, pharmaceutical compositions containing them and process for preparing same
NZ227880A (en) Pyridyl substituted 1,3 dioxane alkenoic acid derivatives and pharmaceutical compositions
FI894812A0 (fi) Menetelmä valmistaa farmakologisesti arvokkaita 2-karbonyylisubstituoituja N,N'-di(trimetoksibentsoyyli)piperatsiineja
GR1000429B (el) Συνθεση με βαση την τριμεβουτινη παρατεταμενης απελευθερωσης και μεθοδος παρασκευης της.
DE2965364D1 (en) Alpha-difluoromethyl amino acids and pharmaceutical composition containing the same
IE790954L (en) Pharmaceutical formulations containing prostaglandin¹compounds
EP0175323A3 (en) Biologically active peptides, processes for preparing them and pharmaceutical compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989911284

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989911284

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1989911284

Country of ref document: EP